Company intelligence / Profile preview

Dova Pharmaceuticals, Inc.

Durham, North Carolina, United Statesdova.com ↗

Ownership: Private
Development stage: Other

Overview

Dova Pharmaceuticals successfully commercialized DOPTELET (avatrombopag), which received FDA approval for thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure, and later received approval for treating thrombocytopenia in adults with chronic immune thrombocytopenia who had insufficient response to previous treatment. The European Commission also granted marketing authorization for DOPTELET for severe thrombocytopenia in adult patients with chronic liver disease scheduled to undergo an invasive procedure.

Therapeutic areas: GastroenterologyHematology
Modalities: Small molecule drug
Industry: Biotech

Partnerships

Salix (for co-promotion of DOPTELET in the United States)

Beyond the preview

Go deeper on Dova Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dova Pharmaceuticals, Inc..